- 1 Title: The Global case-fatality rate of COVID-19 has been declining disproportionately
- 2 between top vaccinated countries and the rest of the world
- 3
- 4 Authors: Najmul Haider¹[†], Mohammad Nayeem Hasan²[†], Rumi A Khan³, David McCoy⁴, Francine
- Ntoumi^{5,6}, Osman Dar⁷, Rashid Ansumana⁸, Md. Jamal Uddin^{2,*}, Alimuddin Zumla^{9,10}, Richard A
 Kock¹
- 7

8 Affiliations:

- 9 ¹ The Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hatfield,
- 10 Hertfordshire, United Kingdom
- ² Department of Statistics, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh.
- 12 ³ Department of Critical Care Medicine, Orlando Regional Medical Centre, Orlando, FL, USA
- ⁴ Institute of Population Health Sciences, Barts and London Medical and Dental School, Queen Mary
- 14 University of London, London, UK
- ⁵ Congolese Foundation for Medical Research, Brazzaville, Republic of Congo.
- ⁶ Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany
- ⁷ Chatham House Centre for Global Health Security, Royal Institute of International Affairs, London,
- 18 UK
- 19⁸ School of Community Health Science, Njala University, Bo Campus, Sierra Leone
- ⁹ Division of Infection and Immunity, Centre for Clinical Microbiology, University College London,
- 21 ¹⁰ NIHR-BRC, University College London Hospitals, London, United Kingdom.
- 22
- 23 † These authors contributed equally
- 24
- 25 *Corresponding author
- 26 Corresponding author address:
- 27 Department of Statistics,
- 28 Shahjalal University of Science and Technology,
- 29 Sylhet 3114, Bangladesh.
- 30 E-mail: jamal-sta@sust.edu
- 31
- 32

33 Abstract

- 34 Globally 58.83% human population received at least one dose of the COVID-19 vaccines as of 5
- 35 January 2021. COVID-19 vaccination rollout is progressing at varied rates globally and data on the
- 36 impact of mass vaccination on infection and case-fatality rates require definition. We compared the
- 37 global reported cumulative case-fatality rate (rCFR) between top-20 countries with COVID-19
- vaccination rates (>125 doses/100 people) and the rest of the world, before and after commencement
- 39 of vaccination programmes.
- 40
- 41 We considered the 28th day of receiving the first vaccine in the world as a cut-off to compare the pre-
- 42 vaccine period (Jan 1, 2020 Jan 5, 2021) and the post-vaccine period (Jan 6, 2021- Jan 5, 2022). We
- 43 used a Generalized linear mixed model (GLMM) with a beta distribution to investigate the association
- between the CFR and potential predictors of each country and reported the relative risk (RR) of each
- 45 variable.
- 46
- 47 The mean rCFR of COVID-19 in the top-20 countries with vaccination rates was 1.83 (95% CI: 1.24-
- 48 2.43) on 5 Jan 2021 and 1.18 (95% CI: 0.73-1.62) on 5 Jan 2022. The CFR for the rest of the world on
- 49 5 Jan 2021 was 2.32 (95% CI: 1.86-2.79) and 2.20 (95% CI: 1.86-2.55) on 5 January 2022. In Sub-
- 50 Saharan Africa, the CFR remained roughly unchanged at 1.97 (95% CI: 1.59-2.35) on 5 Jan 2021 and
- 51 1.98 (95% CI:1.58-2.37) on 5 Jan 2022. The GLMM showed vaccination (/100 population) (RR:0.37)
- 52 and Stringency Index (RR:0.88) were strong protective factors for the country's COVID-19 CFR
- 53 indicating that both vaccination and lockdown measures help in the reduction of COVID-19 CFR.
- 54
- 55 The rCFR of COVID-19 continues to decline, although at a disproportionate rate between top
- 56 vaccinated countries and the rest of the world. Vaccine equity and faster roll-out across the world is
- 57 critically important in reducing COVID-19 transmission and CFR.
- 58
- 59

Key Questions:
What is already known:
• Vaccination can reduce the case-fatality rate of COVID-19. Globally, the COVID-19
vaccination rollout is progressing at varied rates.
What are the new findings?
• In the top-20 countries with vaccination, >200 doses of vaccines are given per 100 people on
5 th Jan 2022, In the rest of the word, the figure is 105, and in Sub-Saharan Africa (SSA) only
15.72
• After the introduction of COVID-19 vaccination the reported case-fatality rate (rCFR) of
COVID-19 has reduced by 35% in the top-20 countries with vaccination, 8% in the rest of the
world roughly unchanged in SSA.
• The doses of COVID-19 vaccines (/100 people) and rCFR has a negative correlation on 5 Jan
2022 (r=-0.296, p<0.001).
The COVID-19 vaccination and Stringency Index are strong protective factors for the
country's COVID-19 rCFR indicating that both vaccination and lockdown measures help in
reduction of COVID-19 rCFR.
What do the new findings imply:
• The disproportionate case-fatality rate of COVID-19 between top vaccinated countries and
the rest of the world demand fast and equitable vaccine rollout globally to reduce COVID-19
transmission and CFR
Keywords: COVID-19, SARS-CoV-2, Case-fatality rate, Vaccine equity, Variants of Concern

87

88 Introduction:

89

90	In the early stages of the COVID-19 pandemic, the WHO-China Joint Mission on Coronavirus
91	Diseases (COVID-19) 28 February 2020 report indicated a crude fatality ratio of 3.8% among the first
92	55,924 laboratory-confirmed cases ¹ . Subsequently, systematic reviews on the case-fatality rate (CFR)
93	of COVID-19 reported an estimated CFR between 2.3-3.6% 2-5. The global cumulative reported case
94	fatality rate (rCFR) of COVID-19 has increased up until the 17th epidemiological week (April 22-28,
95	2020) of detection of SARS-CoV-2 in Wuhan China at 7.2, and then started to decline steadily up
96	until 31 December 2021 at 2.2 ⁶ . The decreasing rate of CFR has been explained by an increased rate
97	of infection in the younger population or by the improvement of health care management, shielding
98	from infection, and/or repurposing of several drugs that had shorted both hospitals stays and saved
99	lives ⁶ . However, during the last quarter of the year, 2020 different variants of concern/Interest
100	(VOC/VOI) of SARS-CoV-2 started to emerge with increased transmissibility 7. Of them, Alpha (first
101	detected in the UK in September 2020), Beta (first documented in South Africa in May 2020),
102	Gamma (first detected in Brazil in November 2020), and Delta (first detected in India in October
103	2020) all reported having higher infectivity and severity than the virus originally detected in Wuhan,
104	China ^{7,8} . During November 2021, a new variant of concern, Omicron was reported to WHO (first
105	reported from South Africa on 24 November 2021)9. Unlike previous VOC, Omicron shows a
106	relatively lower case-fatality rate although the variant has a high transmissibility ^{10,11} .
107	

108 Vaccination can reduce the case-fatality rate of COVID-19. Several vaccines have been approved for 109 emergency use by the Food and Drug Administration, USA, the European Medicine Agency, and the 110 Public Health England and the World Health Organization approved use of a few Vaccines across the 111 world. The real-world data had shown the effectiveness of the vaccines in terms of preventing 112 infection by 60-92%^{12,13}, hospitalization by 87-94%^{12,14} and deaths by 72%- 100%^{12,15} after 7-28 days 113 of receiving the second dose of the vaccines for Alpha, Beta, or Delta VOC.

115	Vaccines are not distributed equitably in the world. Although COVID-19 vaccines were developed at
116	an unprecedented rate through the advancement of science and global cooperation, the distribution of
117	the vaccine across the world is questionable ¹⁶ . Current global vaccination rates of roughly 6.7
118	million doses per day translate to achieving herd immunity in approximately 4.6 years ¹⁶ . Vaccine
119	distribution is absent or very negligible in many of the low-income countries, and experts anticipated
120	that 80% of the population in low-income countries would not receive a vaccine at the end of 2021 16
121	which has been the case.
122	
123	As the world enters the 3 rd year of the COVID-19 pandemic, globally, as of 13 January 2022, there
124	have been over 315,3450, 967 confirmed cases of COVID-19, including 5,510,174 deaths, reported to
125	WHO ¹⁷ . COVID-19 vaccination rollout globally has progressed at varying rates and data on the
126	impact of mass vaccination on infection and case-fatality rates require definition. To this end, we
127	compared the global rCFR between the top-20 countries with vaccination rates (minimum
128	vaccination: 125 dose/100 people) and the rest of the world, before and after commencement of
129	vaccination programs. We further quantified the impacts of vaccinations, other control measures, and
130	relevant variables on Covid-19 CFR.
131	
132	Methods:
133	COVID-19 data
134	The necessary COVID-19 related data, including daily new cases, daily new deaths, total deaths, and
135	total deaths per million inhabitants, vaccination, were collected from the WHO daily COVID-19
136	situation reports of 210 countries from January 01, 2020, to January 05, 2022 ¹⁸ . On 8 th December
137	2020, the first human in the world received an approved COVID-19 vaccine ¹⁹ . We considered
138	the 28th day of receiving the first vaccine in the world as a cut-off to compare the pre-vaccine period
139	(Jan 1, 2020 – Jan 5, 2021) and the post-vaccine period (Jan 6, 2021- Jan 5, 2022).
140	
141	

142 Reported case-fatality rate (rCFR)

We estimated daily cumulative rCFR COVID-19 (please read Hasan et al ⁶ for the definition of rCFR)
as the number of deaths per 100 COVID-19 confirmed cases. In some instances, we aggregated the
daily cases and deaths record by week. As the number of cases and deaths both are a fraction of total
cases or deaths globally, we considered the term as reported CFR or to make a simplified version as
rCFR ⁶.

148

149 Time series model to predict the trend

150 Three forecasting models (i.e., auto-regressive integrated moving average (ARIMA), automatic timeseries forecasting model which is also known as 'Prophet model', and simple exponential smoothing 151 (SES)), to identify the global trend of COVID-19 rCFR. We also used the Mann-Kendall (M-K) trend 152 analysis to identify the presence of any trend and the direction of the trend (increasing or decreasing). 153 We developed a generalized linear mixed model (GLMM) with beta distribution to identify whether 154 the explanatory variables have any relationship between the country's rCFR of COVID-19. These 155 methods supported us to make a credible conclusion on the trend of COVID-19 rCFR over the time. 156 All analyses were carried out using the statistical software R version 3.5.2.2²⁰ and SAS²¹. 157 158 We selected the SES, ARIMA, and Prophet Models because the key outcome variable (rCFR) is 159 dependent on previous records (time-series events) and all these three models can take this into 160 account. Using the time series models with the reported COVID-19 data, we forecasted trends for the 161 prospective 10-days and visualized in the figure. SES is suggested as a good benchmark model to 162 compare the performance of the ARIMA and Prophet models. We also used M-K trend analysis to 163 identify the daily or weekly cumulative trend (increasing or decreasing) of COVID-19 rCFR²². The 164 details of the SES, ARIMA, and Prophet models are discussed in an earlier article on COVID-19⁶. 165 166

167 Outcome and predictor variables

We collected a selected number of predictors variables from the World Bank and other UN sources
such as population density ²³, percentage of people above 65 years of age ²⁴, Gross Domestic Product

(GDP)²⁵, worldwide governance indicators (WGI)²⁶, and Global Health Security Index (GHSI)²⁷, the 170 prevalence of obesity ²⁸ or from "Our World in Data" ²⁹ in our analyses. We also included the 171 country-specific prevalence of diabetes ²⁹ and cardiovascular disease ²⁹ to explain the variation of 172 COVID-19 rCFR. The GHSI index scored between 0 and 100 to indicate the country's capacity for 173 early detection and reporting for epidemics ²⁷. The WGI scored between -2.5 and 2.5, where -2.5 174 indicates the weakest and 2.5 indicates the strongest governance performance ²⁶. The Oxford 175 COVID-19 Government Response Tracker systematically collects information from 148 countries on 176 177 several policy responses that governments have taken, scores stringency of such measures, and aggregates them into a common Stringency Index (SI) in a daily basis ³⁰. In the Our World in Data ²⁹, 178 the SI was calculated by using nine response indicators including school closures, workplace closures, 179 and travel bans, rescaled to a value from 0 to $100 (100 = \text{strictest})^{30}$. The value of the SI at any given 180 181 day is the results of the mean of the nine indicators. Thus, the index reports a number that reflects the overall stringency of the government's response. Higher index indicates a better overall response level 182 30 183

184

185 Empirical evaluation

We assessed the ARIMA and Prophet models by comparing their results to benchmarks model, the SES ³¹. The SES also allows the most appropriate non-seasonal model for each series, allowing for any kind of error or trend component. We, then, analyse and compared the performance of the performance of the time series models with some of the commonly used measures to evaluate the prediction significance including coefficient of determination (R^2), root mean square error (RMSE), and mean absolute error (MAE).

192

193 Generalized Linear Mixed Models

194 The Generalized Linear Mixed Models (GLMM) is an extension of the Generalized Linear Models195 (GLM) that allows the analysis of clustered categorical data, as in the case of repeated responses from

different subjects ³². One of the key advantages of GLMM is that it separates the levels of the models

197 to account for the group effect nesting the lower-level observations. In this study, locations are treated

198 as the second level which group sequential observations within the same area, and independent variables are treated as repeated observations at the lower level. While the location data are assumed 199 to be time-invariant, the independent data are assumed to be universal over the whole study area at a 200 201 certain time point. The model describes a beta distribution family that has a logit link. We conducted 202 GLMMs using the statistical software R³³. 203 204 **Statistical analysis** We performed summary statistical of vaccine doses/100 inhabitant and rCFR by country in the top-20 205 206 countries with vaccination rate, in SSA and in the rest of the world pre-and post-vaccination 207 programme and reported the mean and inter-quantile range (IQR). We observed that the rCFR of 208 COVID-19 has changed over time (Fig. 1). Using time-series models alone would not allow us to 209 identify the reason behind the increasing and decreasing trend of COVID-19 rCFR. We explored whether the relationship between the rCFR of COVID-19 and country-level explanatory variables 210 vary over time through generalized linear mixed models. As the trend of rCFR in both periods is 211 212 different, we ran generalized linear mixed models to investigate the association between possible explanatory variables and tried to investigate which variables affect the most in both periods 213 214 separately. 215 216 **Patient and Public Involvement** This study is based on different country's COVID-19 cases and deaths record reported to WHO. The 217 study does not include any individual patient level data. The findings of the results will be helpful in 218 the equitable distribution of COVID-19 vaccines. The authors acknowledge the authorities shared the 219 COVID-19 cases and deaths record. Patients or members of the public were not involved in the 220 design, conduct, reporting or dissemination plans of the research as it was neither appropriate to 221 222 involve nor possible to include. 223 224

226 **RESULTS:**

227

228	More than 297.77 million cumulative confirmed cases and 5.47 million deaths had been documented
229	globally on 5 Jan 2022. More than 127.50 doses of COVID-19 vaccines are given per 100 population
230	globally as of 5 January 2022. For every 100 people, 201.11 doses of vaccines are given in the top-20
231	countries with COVID-19 vaccination rates, in the rest of the world, 105.20 doses of COVID-19
232	vaccines are given, whereas the number is just 15.72 in Sub-Saharan Africa (SSA) (Table 1). The
233	global reported CFR is estimated as 1.83 on 5 th January 2021 which is has dropped by 35.5% at 1.18%
234	on 5 th January 2022 in the top-vaccinated country. In the rest of the world the rCFR dropped from
235	2.32 on 5 th January 2021 to 2.2 on 5 th January 2022, reduced by only 8.4% only (Table 1). In the
236	SSA, the rCFR has increased by 0.5% over the period (1.97 vs. 1.98). The top five countries with
237	COVID-19 rCFR as of 5 Jan 2022 are Yemen (19.56%), Peru (8.75%), Mexico (7.44%), Sudan
238	(7.07%), and Ecuador $(6.09%)$. The correlating coefficient between vaccination rate (/100 people) and
239	rCFR in different countries of the world on 5 Jan 2022 is estimated as -0.296 (p<0.001) (Fig 2).

- 240
- 241 Table 1: The doses of COVID-19 vaccines and reported case-fatality rate (rCFR) of COVID-19
- in the top-20 vaccinated countries and rest of the world during 5th Jan 2021 and 5th Jan 2022.

	Top-20 countries	Rest of the	Global	Sub-Saharan
	with vaccination	world	Mean (IQRs)	Africa
	rates	Mean (IQRs)		Mean (IQRs)
	Mean (IQRs)			
Vaccination Doses/100 People (5 January 2022)	201.11 (190.38 – 211.84)	105.20 (91.28 – 119.11)	127.50 (113.56 - 141.44)	15.72 (35.31 – 26.12)
Reported CFR by 5 Jan 2021	1.83 (1.24 - 2.43)	2.32 (1.86 - 2.79)	2.26 (1.85 - 2.67)	1.97 (1.59 – 2.35)
Reported CFR by 5 January 2022	1.18 (0.73 – 1.62)	2.20 (1.86 – 2.55)	2.07 (1.76 - 2.39)	1.98 (1.58 – 2.37)
p-value (for differences of rCFR between 5 Jan 2021 and 5 Jan 2022)	0.001	0.340	0.069	0.972

245 Factors associated with rCFR: 246 In the GLMM, the estimated effect of each variable is presented in relative risk (RR) and its 247 significance is shown by its p-value. The COVID-19 vaccination (0.37 [0.19–0.57]), GDP (0.75 248 249 [0.64–0.87]), and stringency index (0.88 [0.86–0.89]) was negatively significantly associated with the 250 COVID-19 rCFR indicating that vaccination, GDP and lockdown measures all contributed to reduction of rCFR of COVID-19. The percentage of people aged 65 years or above the age of the 251 252 population of the country were significantly positively (RR: 1.17, 95% CI: 1.01–1.37) associated with 253 COVID-19 rCFR (Table 2). 254 The table includes the various covariates and the random intercept in the model. The intraclass 255 correlation coefficient (ICC) of 0.634 was calculated by dividing the variance of the random effect by 256 257 the total variance. Thus, the spatial unit effects account for approximately 63.4% of the total variance of weekly rCFR, which suggests moderate reliability on location effects on weekly rCFR. It is also to 258 be noted that with the introduction of a random intercept, "vaccination", "population density", 259 "GDP", "weeks" and "stringency index" had significant negative effects on weekly rCFR and "the 260 261 percentage of people aged 65 and above" have significant positive effects. 262 Table 2: Factors associated with reported Case-Fatality Rate (rCFR) of COVID-19 in different 263 counties of the world using a generalized linear mixed model during 1st Jan 2020 and 5th Jan 264 265 2022.

266

244

Variables	Relative Risk	95% Confidence	P-value
	[RR]	Interval	
Vaccination	0.374	0.191 - 0.567	< 0.001 ***
The percentage of people aged 65	1.170	1.011 - 1.375	0.049*
and above			
Population density	0.895	0.798 - 1.002	0.048*
GDP	0.746	0.643 - 0.870	< 0.001 ***
GHSI	1.123	0.955 - 1.321	0.150
WGI	1.050	0.906 - 1.213	0.500
Obesity (%)	1.121	0.993 - 1.269	0.060
Stringency index	0.882	0.864 - 0.887	< 0.001 ***
Vaccination: Weeks	1.207	1.103 - 1.402	< 0.001 ***
Weeks	0.914	0.817 - 0.955	0.015 **
Groups Name	Variance	Standard Deviation	
Location (Intercept)	0.3354	0.5791	
Weeks (Intercept)	0.0274	0.1655	
Akaike information criterion	-201305.5	Conditional R ²	0.710
(AIC)			
Bayesian Information	-201201.0	Marginal R ²	0.207
Criterion (BIC)			
Root Mean Square Error	0.021	Intraclass	0.634
(RMSE)		correlation (ICC)	

267

268 The Trend of global rCFR of COVID-19:

269 In the ARIMA and Prophet Model, we found a strong declining trend of rCFR of COVID-19 between

observed and predictive global rCFR of COVID-19 with an R^2 , RMSE, and MAE value of 99.94%

and 99.56%, 0.04 and 0.13, and 0.01 and 0.06, respectively (Table 3). In terms of accuracy, the

ARIMA model performed better over Prophet and SES model (with better R^2 , RMSE, and MAE

value). The coefficient of determination of the ARIMA model was larger and errors are lower than

274 Prophet and SES model. According to the forecast in both models, the ratio of COVID-19 rCFR is

expected to decrease considerably in the coming 10 days (Fig 1). In M-K trend analysis, we found a

negative trend of cumulative rCFR (p < 0.001 and tau = -0.79). In Sen's slop test, the slope was -0.02

277 (95% CI: -0.03 to -0.01).

278

279 Table 3. The summary of Simple Exponential Smoothing (SES), Auto-Regressive Integrated Moving

280 Average (ARIMA), Automatic forecasting time-series model (Prophet), Mann-Kendall (M-K), trend

and Sen's slope analysis. The SES, ARIMA, and Prophet models used daily cumulative reported case-

fatality rate (rCFR) data whereas the M-K trend analysis and Sen's slop used weekly cumulative

- 283 rCFR data. The Kendall's Tau value permits a comparison of the strength of correlation between two
- data series (here, week of the year 2020 and rCFR)²².
- 285

Method & Period	Period RMSE M		
Simple Exponential Smoothing			
Overall	99.91%	0.04	0.01
Auto-Regressive Integrated Moving Average			
Overall ARIMA (4,1,3)	99.94%	0.04	0.01
Automatic Forecasting time-series model			
Overall	99.56%	0.13	0.06
Mann-Kendell trend analysis			
	tau	Р	
	-0.79	< 0.001	
Sen's slop test			
	Sen's Slope	95% CI	
	-0.02	-0.03 to -0.	.01

²⁸⁶

RMSE: Root Mean Square Error; MAE: Mean Absolute Error

287

288

289 **Discussion:**

290

291 The global rCFR of COVID-19 has been declining since May 2020 and the rate become plateaued or

slightly increased with the emergence of different variants of concerns especially after the emergence

and spreading of Delta VOC of SARS-CoV-2³⁴. After the beginning of COVID-19 vaccines rollout,

the rCFR started to decline, although, at a different rate in top-20 countries with vaccination rates, and

the rest of the world. In SSA, where the vaccine rollout did not reach to a satisfactory mark yet, the

rCFR of COVID- 19 remained constant. Many factors affect the reduction of rCFR, however, our

analysis indicates that the combination of vaccination, lockdown measures (stringency index), and the

298 country's GDP is contributing significantly to the reduction of rCFR. Earlier studies discussed

299 potential role of an increased rate of infection in younger people or by the improvement of health care management, shielding from infection, and/or repurposing of several drugs had a beneficial effect on 300 reducing the fatality rate of COVID-19. This analysis complements previous findings, however, 301 generating immediate impact of inequitable vaccine rollout globally, indicating the importance of 302 303 equitable distribution of COVID-19 vaccine to reduce fatalities due to COVID-19. 304 305 The negative correlation between doses of COVID-19 vaccines given and rCFR indicates the 306 effectiveness of vaccines in reducing COVID-19 related deaths globally. The vaccines thus provide a 307 pathway out of this pandemic, but strong, innovative policies that ensure fast and equitable distribution are absent ¹⁶. Vaccinating the world serves global interests of protecting each other's 308 health, and economy ¹⁶. Unless the vaccine reaches to a level of global herd immunity, these goals 309 310 will not be accomplished ¹⁶. Our analysis showed a great difference of vaccine roll out in top 311 vaccinated counties (201 doses/100 people) and the low-income countries (e.g. 15 doses/100 people in SSA) on 5 Jan 2022³⁵. In high-income countries, third or even fourth dose of the COVID-19 vaccine 312 programmes are ongoing ³⁶ whereas more than 80% of people in the SSA did not receive a single dose 313 314 of vaccine yet (as of 5 Jan 2022). The high-income countries organization (G7) nations have 315 committed support for global vaccine procurement through the Covid-19 Vaccines Global Access (COVAX) program, which supplies vaccines to low-and-middle-income countries. Currently, 316 COVAX planned to vaccinate at least 30% of the population of 92 low-and -middle income countries 317 by the end of 2022 37 . 318

319

We found the COVID-19 vaccination, stringency index, and GDP as significantly associated with the reduction of rCFR of COVID-19. The major vaccines (mRNA, or adenovirus vectored) all are highly effective in reducing hospital admission and deaths ³⁵, even though some of the vaccines were not very effective in limiting the infection ³⁵. Thus, the vaccine rollout helped the high-income countries quickly reduce the burden of patients in hospitals thus limiting fatalities of COVID-19. However, in the rest of the world where vaccine rollout is still far from achieving herd immunity (70-80% of people receiving full doses of vaccines) the case-fatality rate has not declined significantly compared

to that of the top vaccinated countries. However, in many countries especially in SSA, the natural
infection had reached in a state to limit the infection and reduce the overall burden of the pandemic ³⁸.
In the Republic of Congo 66% of people in Brazzaville ³⁹ in Malawi, 64.9% of blood donors ⁴⁰ and in
the Central African Republic, 74% of community residents had antibodies to SARS-CoV-2 ⁴¹.
Lockdown measures indicated as Stringency index has been associated with reduction of CFR of
COVID-19. The Stringency index is a composite measure based on indicators including school
closure, workplace closure, travel bans, and use of mask, and other social distancing practices. This

has been associated with shielding vulnerable people from infection and contributes to the reduction

fatalities of COVID-19 in high-income countries ⁴², in Africa, lockdown has shown low or no benefit

of COVID-19 related fatalities. While lockdown has been shown beneficial in reducing cases and

in terms of limiting transmissions ⁴³. The country's GDP is another indicator associated with the

reduction of COVID-19 rCFR. This is believed that countries with higher national income deployed

341 allowing them to concentrate on the vulnerable population, all synergistically helping them reduce the

vaccines at a faster rate which reduce the local transmission and reduced rate of hospitalization thus

342 fatalities of COVID-19. Earlier studies have also identified these variables as a risk factors/protective

factors for mortality/fatality rate of COVID-19^{6,44,45}.

344

340

336

Equitable distribution of SARS-CoV-2 vaccines is crucial to ending the COVID-19 pandemic ⁴⁶. The 345 circulation of the SARS-CoV-2 across the world among the large unvaccinated populations might 346 allow the virus to reassort to become a new VOC. Furthermore, many animal species are susceptible 347 to SARS-CoV-2 including Mink, Primates, rodents, cats, and dogs ⁴⁷. Earlier studies showed the link 348 of animal species in the generation of VOC including dogs for Alpha variant ⁴⁸ and rodents for 349 Omicron variant ⁴⁹. Thus, this is important to reduce the circulation of SARS-CoV-2 in the human and 350 animal populations to avoid further epidemics caused by new VOC. Equitable and faster vaccine 351 rollout is the key to reducing the circulation of SARS-CoV-2 across the world. 352

353

354 Limitation:

The case, death record, and the number of people being tested are reported based on the number 355 shared by countries of the world. However, different countries have different capabilities of testing 356 populations, and countries used different strategies to test their population which has affected the 357 358 reported cases and deaths figures. This ultimately affected our estimated CFR of COVID-19. However, this is a global issue, and we accept this limitation and thus refer to the CFR as reported 359 CFR, not true Case-fatality rate. Also, this terminology should not be confused with the infection 360 361 fatality rate. Although we found that vaccination and lockdown measures both are associated with the 362 reduction of COVID-19 CFR, however, we could not differentiate the true impact of each measure 363 separately although the RR of the vaccination is estimated as four times more effective compared to 364 the lockdown measures. 365 366 **Conclusion:** 367 368 More than 201 doses of COVID-19 vaccines have been given per 100 people in the top-20 countries with higher vaccination rates, compared to 105 doses in the rest of the world and 16 doses in Sub-369 Saharan Africa as of 5th Jan 2022. Vaccination and reported CFR (rCFR) of COVID-19 has a negative 370 correlation (-0.29) on 5 Jan 2022 indicating the effectiveness of the vaccines in reducing COVID-19 371 related deaths. Globally, the reported CFR (rCFR) of COVID-19 has been declining since the 372 beginning of the vaccination programme. However, the rCFR has dropped significantly in the top-20 373 countries with vaccination rates (35%) compared to the rest of the world (8%), whereas it remained 374 largely unchanged in Sub-Saharan Africa (1.97 on 5th Jan 2021 and 1.98 on 5th Jan 2022). The 375 COVID-19 vaccination, lockdown measures, and country's GDP were associated with reduction of 376 rCFR of COVID-19. Vaccine equity and faster roll-out across the world is critically important in 377 reducing COVID-19 transmission and CFR. 378 379

380

381	Contr	ibution: NH and RK originally planned the study, MNH collected the data, NH and MNH,
382	MJU a	nalyzed the data. NH prepared the first draft manuscript and MNH, RAK, DM, FN, OD, RA,
383	MJU,	AZ and RK reviewed the draft manuscripts. All authors approved the submission of the
384	manus	cript.
385		
386	Ackno	owledgements
387	NH, F	N, OD, RA AZ, RK are part of PANDORA-ID-NET Consortium (EDCTP Reg/Grant
388	RIA20	16E-1609) funded by the European and Developing Countries Clinical Trials Partnership
389	(EDC	ΓP2) programme, which is supported under Horizon 2020, the European Union's Framework
390	Progra	mme for Research and Innovation.
391		
392	Confli	ict of interest: The authors declare that they have no conflict of interest
393		
394	Fundi	ng Source: There was no funding for this research.
395		
396	Ethica	al approval: This study does not include any individual-level data and thus does not require any
397	ethical	approval.
398		
399	Data s	sharing statement: All the data presented in this manuscript are publicly available in "Our
400	World	in Data", "WHO" or "United Nations" webpages. However, the corresponding author can be
401	reache	d to specific queries on the data sources.
402	Refer	ences:
403 404	1	WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva, Switzerland, 2020.
405 406 407	2	Ahammed T, Anjum A, Rahman MM, Haider N, Kock R, Uddin MJ. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: A systematic review and meta-analysis. <i>Heal Sci Reports</i> 2021; 4 : 1–11.
408 409 410	3	He W, Yi GY, Zhu Y. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis. <i>J Med Virol</i> 2020; published online May. DOI:10.1002/jmv.26041.
411	4	Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease

Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease

412 Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 413 414 145-51. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) 415 5 in China: A systematic review and meta-analysis. J Infect 2020; 80: 656-65. 416 417 6 Hasan MN, Haider N, Stigler FL, et al. The Global Case-Fatality Rate of COVID-19 Has Been Declining Since May 2020. Am J Trop Med Hvg 2021; 104: 2176-84. 418 419 7 Mahase E. Covid-19: How many variants are there, and what do we know about them?: Video 1. BMJ 2021; 374: n1971. 420 Mahase E. Covid-19: Death rate is 0.66% and increases with age, study estimates. BMJ. 2020. 421 8 DOI:10.1136/bmj.m1327. 422 9 Petersen E, Ntoumi F, Hui DS, et al. Emergence of new SARS-CoV-2 Variant of Concern 423 424 Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and 425 426 control efforts. Int J Infect Dis 2022; 114: 268-72. 427 10 UK Health Security Agency. SARS-CoV-2 variants of concern and variants under 428 investigation in England- Technical briefing: Update on hospitalisation and vaccine 429 effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). London, 2021. Jassat W, Karim SA, Mudara C, et al. Clinical Severity of COVID-19 Patients Admitted to 430 11 431 Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave. SSRN 432 Electron J 2021. DOI:10.2139/ssrn.3996320. 433 12 Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide 434 Mass Vaccination Setting. N Engl J Med 2021; 384: 1412-23. 13 Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and 435 436 Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and 437 mortality in older adults in England: test negative case-control study. BMJ 2021; : n1088. 14 438 Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 439 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021; 397: 1646-57. 440 Murillo-Zamora E, Trujillo X, Huerta M, Riós-Silva M, Mendoza-Cano O. Effectiveness of 441 15 BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among 442 443 Healthcare Workers. Medicina (B Aires) 2021; 57: 746. 444 16 Katz IT, Weintraub R, Bekker L-G, Brandt AM. From Vaccine Nationalism to Vaccine Equity 445 — Finding a Path Forward. N Engl J Med 2021; **384**: 1281–3. Worldometer. Coronavirus Cases. Worldometer. 2020; : 1-22. 446 17 447 18 WHO. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. Geneva, Switzerland, 2022. 448 19 BBC News. No TitleCovid-19 vaccine: First person receives Pfizer jab in UK. BBC. 2020; : 449 450 Available at: https://www.bbc.co.uk/news/uk-552273. 451 20 R Core Team. R: A Language and Environment for Statistical Computing. 2020. SAS Institute Inc. Cary, NC U (2016). SAS Statistical Software, 2017. 21 452 453 22 Yue S, Pilon P. A comparison of the power of the t test, Mann-Kendall and bootstrap tests for 454 trend detection / Une comparaison de la puissance des tests t de Student, de Mann-Kendall et

medRxiv preprint doi: https://doi.org/10.1101/2022.01.19.22269493; this version posted January 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	polpolany.	
It is made available under a	a CC-BY-NC 4.0	International license.

455		du bootstrap pour la détection de tendance. <i>Hydrol Sci J</i> 2004; 49 : 21–37.
456 457	23	World Data Bank. Population density (people per sq. km of land area). World Dev. Indecators. 2018.
458	24	The World Bank. Population ages 65 and above, total. World Bank Data. 2018.
459	25	The World Bank. GDP (current US\$) Data. World Bank. 2018.
460	26	WGI. WGI 2019 Interactive. WGI 2019. 2019; : 1.
461 462	27	Nuclear Threat Initiative (NTI), Johns Hopkins Center for Health Security (JHU). GHS Index. 2020.
463	28	WHO. Global health services data, obesity and overweight. 2020.
464	29	Data OW in. COVID-19: Stringency Index, Oct 2, 2021. 2021.
465 466	30	Oxford COVID-19 Government Response Tracker. Calculation and presentation of the Stringency Index 4.0 28 April 2020. Oxford, 2020.
467 468	31	Kourentzes N, Petropoulos F. Forecasting with multivariate temporal aggregation: The case of promotional modelling. <i>Int J Prod Econ</i> 2016; 181 : 145–53.
469 470	32	Samur AA, Coskunfirat N, Saka O. Comparison of predictor approaches for longitudinal binary outcomes: application to anesthesiology data. <i>PeerJ</i> 2014; 2 . DOI:10.7717/PEERJ.648.
471 472	33	R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
473 474 475	34	Zhao S, Lou J, Cao L, <i>et al.</i> Differences in the case fatality risks associated with SARS-CoV-2 Delta and non-Delta variants in relation to vaccine coverage: An early ecological study in the United Kingdom. <i>Infect Genet Evol</i> 2022; 97 : 105162.
476 477 478	35	Altarawneh H, Chemaitelly H, Tang P, R MH, Abu-Raddad LJ. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. <i>medrXiv</i> 2022; https://do . DOI:https://doi.org/10.1101/2022.01.05.22268782.
479	36	Iacobucci G. Covid-19: Fourth vaccine doses—who needs them and why? BMJ 2022; : o30.
480 481	37	Mullard A. How COVID vaccines are being divvied up around the world. <i>Nature</i> 2020; published online Nov 30. DOI:10.1038/d41586-020-03370-6.
482 483 484	38	Mukwege D, Byabene AK, Akonkwa EM, <i>et al.</i> High SARS-CoV-2 Seroprevalence in Healthcare Workers in Bukavu, Eastern Democratic Republic of Congo. <i>Am J Trop Med Hyg</i> 2021; 104 : 1526–30.
485 486	39	Ingoba LL, Ntoumi F. Seroprevalence of SARS-CoV-2 among residents of Brazzaville, the Republic of Congo. In: EDCTP Forum. Maputo, Mozambique, 2021.
487 488 489	40	Mandolo J, Msefula J, Henrion MYR, <i>et al.</i> SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. <i>BMC Med</i> 2021; 19 : 303.
490 491 492	41	Alexandre M, Christian M, Brice MY, <i>et al.</i> Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic. <i>medXiv</i> 2021; Nov 21 : Available at: https://doi.org/10.1101/2021.11.18.2.
493 494 495	42	Lau H, Khosrawipour V, Kocbach P, <i>et al.</i> The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. <i>J Travel Med</i> 2020; 27 . DOI:10.1093/jtm/taaa037.

43	Haider N, Osman AY, Gadzekpo A, <i>et al.</i> Lockdown measures in response to COVID-19 in nine sub-Saharan African countries. <i>BMJ Glob Heal</i> 2020; 5 : e003319.
44	Haider N, Yavlinsky A, Chang Y-M, <i>et al.</i> The Global Health Security index and Joint External Evaluation score for health preparedness are not correlated with countries' COVID-19 detection response time and mortality outcome. <i>Epidemiol Infect</i> 2020; 148 : e210.
45	Kim J, Hong K, Yum S, <i>et al.</i> Factors associated with the difference between the incidence and case-fatality ratio of coronavirus disease 2019 by country. <i>Sci Rep</i> 2021; 11 : 18938.
46	Michie S, Bullen C, Lazarus J V., <i>et al.</i> Vaccine Equity Is Crucial to End the COVID-19 Pandemic — But It Won't Be Enough. 2021.
47	Haider N, Rothman-Ostrow P, Osman AY, et al. COVID-19—Zoonosis or Emerging Infectious Disease? Front Public Heal 2020; 8: 1–8.
48	Zhang J, Zhang Y, Kang J-Y, <i>et al.</i> Potential transmission chains of variant B.1.1.7 and co- mutations of SARS-CoV-2. <i>Cell Discov</i> 2021; 7: 44.
49	Wei C, Shan K-J, Wang W, Zhang S, Huan Q, Qian W. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. <i>J Genet Genomics</i> 2021; published online Dec. DOI:10.1016/j.jgg.2021.12.003.
Figur	e legends:
Figur	e 1. Top: Observed and predicted global daily reported Case-Fatality Rate (rCFR) using Simple
Expor	nential Smoothing (SES) model. Middle: Observed and predicted daily worldwide daily
cumu	lative rCFR using Auto-Regressive Integrated Moving Average (ARIMA) model. Bottom:
Obser	ved and predicted daily worldwide daily cumulative rCFR using Automatic Forecasting time-
series	model (Prophet model). The black dots indicate observed data, the blue line indicates the
predic	ctive CFR, and the shaded area indicates the 95% confidence interval of predicted CFR.
Figur	e 2: The map shows the Covid-19 vaccination rate (/100 people) and the reported Case-fatality
rate (r	CFR) in different countries of the world on 5 January 2022. The darker colour indicates the
highe	r vaccination rates or higher case-fatality rates. An opposite correlation exists between COVID-
19 va	ccination rate and rCFR (r= -0.296 p<0.001)
	 43 44 45 46 47 48 49 Figur Figur Export cumult Obsert serties predict Figur rate (red) higher 19 vac

527

529 Fig 1:



534 Fig 2







2.5

535

536

Simple Exponential Smoothing Model Reported CFR (%) Observed data - 80% - 95% - Fitted - Forecast Auto-Regressive Integrated Moving Average Model Reported CFR (%) 6 -4 -Observed data - 80% - 95% - Fitted - Forecast Automatic Forecasting Time-series Model Reported CFR (%) 6 -2 2020-01 2020-07 2021-07 2021 2022-01

Months







Reported CFR (%)

